Page 18 - Read Online

Page 12 of 12 Rutledge et al. Hepatoma Res 2019;5:31 I http://dx.doi.org/10.20517/2394-5079.2019.19

41. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus
infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493-505.
42. Jacobson I, Poordad F, Firpi-Morell R, Everson G, Verna E, et al. O008: Efficacy and safety of grazoprevir and elbasvir in hepatitis C
genotype 1-infected patients with child-pugh class B cirrhosis (C-salt part A). J Hepatol 2015;62:S193-S4.
43. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated
cirrhosis. N Engl J Med 2015;373:2618-28.
44. Aqel BA, Pungpapong S, Leise M, Werner K, Chervenak AE, et al. Multicenter experience using simeprevir and sofosbuvir with or
without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015;62:1004-12.
45. Deuffic-Burban S, Mathurin P, Rosa I, Bouvier AM, Cannesson A, et al. Impact of emerging hepatitis C virus treatments on future
needs for liver transplantation in France: a modelling approach. Digest Liver Dis 2014;46:157-63.
46. Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, et al. Future of liver disease in the era of direct acting antivirals for the
treatment of hepatitis C. World J Hepatol 2017;9:352-67.
47. Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, et al. Cost effectiveness of direct-acting antiviral therapy for treatment-naive
patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol 2013;11:1503-10.
48. He T, Lopez-Olivo M, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C
genotypes 2-6. Aliment Pharmacol Ther 2017;46:711-21.
49. Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment
with direct-acting antivirals. Pharmacoeconomics 2016;34:551-67.